Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: Application of in vitro approaches to predicting in vivo reduction of (S)-warfarin clearance

Drug Metabolism and Disposition

Volumn 27, Issue 10, 1999, Pages 1179-1186

  Takahashi, Harumi ^a   Kashima, Toshitaka ^b   Kimura, Sosuke ^b   Murata, Noboru ^c   Takaba, Toshihiro ^c   Iwade, Kazunori ^d   Abe, Tomio ^e   Tainaka, Hitoshi ^f,h   Yasumori, Toshio ^g,i   Echizen, Hirotoshi ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c SHOWA UNIVERSITY   (Japan)

^d YOKOHAMA NATIONAL UNIVERSITY   (Japan)

^e SAPPORO MEDICAL UNIVERSITY   (Japan)

^f Mitsui Eng Shipbuilding Co Ltd   (Japan)

^g KEIO UNIVERSITY   (Japan)

^h Iwaki Glass Co   (Japan)

ⁱ BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUCOLOME; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG POTENCY; DRUG POTENTIATION; FEMALE; HUMAN; HYPERURICOSURIA; INTERNATIONAL STANDARD UNIT; LIVER MICROSOME; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; BARBITURATES; BLOOD PROTEINS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROTEIN BINDING; STEREOISOMERISM; WARFARIN;

EID: 0032875675     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Aarons LJ and Rowland M (1981) Kinetics of drug displacement interactions. J Phamacokinet Biopharm 9:181-190.
2. Abe H, Sawada M, TodaT, Kurosawa N, Owada E, Tazawa I and Sakuma S (1995) Evaluation of co-administration of bucolome for warfarin therapy from the view point of protein binding. Jpn J Ther Drug Monit 12:293-298.
3. Blum RA, D'Andrea DT, Florentino BM, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Goldstein H and Schentag JJ (1991) Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 114:755-757.
4. Chan E, McLachlan A, O'Reilly R and Rowland M (1994) Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther 56:286-294.
5. Ervine CM and Houston JB (1994) Disposition of azole antifungal agents. III: Binding of fluconazole and other azoles in rat liver. Pharm Res 11:961-965.
6. Giga-Hama Y, Tohda H, Okada H, Owada MK, Okayama H and Kumagai H (1994) High-level expression of human lipocortin I in the fission yeast Schizosaccharomyces pombe using a novel expression vector. Biotechnology 12:400-404.
7. Haining RL, Hunter AP, Veronese ME, Trager WF and Rettie AE (1996) Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 333:447-458.
8. Hall SD, Hamman MA, Rettie AE, Wienkers LC, Trager WF, Vandenbranden M and Wrighton SA (1994) Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. Drug Metab Dispos 22:975-978.
9. Harder S and Thürmann P (1996) Clinically important drug interactions with anticoagulants: An update. Clin Pharmacokinet 30:416-444.
10. Heimark LD, Wienkers L, Kunze K, Gibaldi M, Eddy AC, Trager WF, O'Reilly RA and Goulart DA (1992) The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 51:398-407.
11. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D and Brandt JT (1998) Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 114:4458-4695.
12. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacol Rev 50:387-411.
13. Kakemi K, Arita T, Hashi M and Sumii K (1966) Binding of 1-cyclohexyl-5-n-butyl-2,4,6-trioxoperhydropyrimidine with serum albumin. Yakugaku Zasshi 86:739-744.
14. Kunze KL and Trager WF (1996) Warfarin-fluconazole III: A rational approach to management of a metabolically based drug interaction. Drug Metab Dispos 24:429-435.
15. Mashima T, Hosono K and Kawabe A (1974) A new method of anticoagulant therapy used by combination warfarin and bucolome. Niigata Igakukai Zasshi 88:95-119.
16. O'Reilly RA (1974) Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 16:348-354.
17. O'Reilly RA, Goulart DA, Kunze KL, Neal J, Gibaldi M, Eddy AC and Trager WF (1992) Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 51:656-667.
18. Poli-Scaife S, Attias R, Dansette PM and Mansuy D (1997) The substrate binding site of human liver cytochrome P450 2C9: An NMR study. Biochemistry 36:12672-12682.
19. Porter RS and Sawyer WT (1992) Warfarin, in Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring (Evans WE, Schentag JJ and Jusko WJ eds) pp 31(1)31(46), Applied Therapeutics, Vancouver.
20. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzales FJ and Trager WF (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59.
21. Segel IH (1993) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. John Wiley and Sons, New York.
22. Shaw PN and Houston JB (1987) Kinetics of drug metabolism inhibition: Use of metabolite concentration-time profiles. J Pharmacokinet Biopharm 15:497-510.
23. Sugiyama Y, Iwatsubo T, Ueda K and Ito K (1996) Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: Pharmacokinetic consideration. J Toxicol Sci 21:309-316.
24. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349.
25. Takahashi H, Kashima T, Kimura S, Muramoto N, Nakahata H, Kubo S, Shimoyama Y, Kajiwara M and Echizen H (1997) Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection. J Chromatogr B 701:71-80.
26. 359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 8:365-373.
27. Toon S, Low LK, Gibaldi M, Trager WF, O'Reilly RA, Motley CH and Goulart DA (1986) The warfarin-sulfinpyrazone interaction: Stereochemical considerations. Clin Pharmacol Ther 39:15-24.
28. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Prichard GA, Eugene Wright C and Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379.
29. von Moltke LL, Greenblatt DJ, Schmider J, Eugene Wright C, Harmatz JS and Shader RI (1998) In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 55:113-122.
30. Wagner JG and Ayres JW (1977) Bioavailability assessment: Methods to estimate total area (AUC 0-∞) and total amount excreted (Ae∞) and importance of blood and urine sampling scheme with application to digoxin. J Pharmacokinet Biopharm 5:533-557.
31. Wells PS, Holbrook AM, Crowther NR and Hirsh J (1994) Interactions of warfarin with drugs and food. Ann Intern Med 121:676-683.
32. Wilkinson GR and Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
33. Wilting J, van der Giesen WF, Janssen LHM, Weideman MM, Otagiri M and Perrin JH (1980) The effect of albumin conformation on the binding of warfarin to human serum albumin: The dependence of the binding of warfarin to human serum albumin on the hydrogen, calcium, and chloride ion concentrations as studied by circular dichroism, fluorescence, and equilibrium dialysis. J Biol Chem 255:3032-3037.
34. Yashiki T (1971) Metabolic fate and the pharmacokinetics of 5-n-butyl-1-cyclohexyl-2,4,6-trioxoperhydropyrimidine (BCP) in man. J Takeda Res Lab 30:801-840.
35. Yasumori T (1997) Expression of a human cytochrome P450 in Schizosaccharomyces pombe: Comparison with expression in Saccharomyces cerevisiae, in Foreign Gene Expression in Fission Yeast Schizosaccharomyces pombe (Giga-Hama Y and Kumagai H eds) pp 111-121, Springer-Verlag and Landes Bioscience, Georgetown.
36. Yasumori T, Li QH, Yamazoe Y, Ueda M, Tsuzuki T and Kato R (1994) Lack of low km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4′-hydroxylation. Pharmacogenetics 4:323-331.